Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome

Authors Ruchi Mathur, Olga Levin, Ricardo Azziz

Published 11 April 2008 Volume 2008:4(2) Pages 487—492

DOI https://doi.org/10.2147/TCRM.S6864

Ruchi Mathur1, Olga Levin1, Ricardo Azziz1

1Cedars-Sinai Medical Center, Los Angeles, CA, US

Abstract: Polycystic ovary syndrome (PCOS) is one of the most common endocrine/metabolic disorders found in women, affecting approximately 105 million women worldwide. It is characterized by ovulatory dysfunction, often presenting as oligomenorrhea or amenorrhea and either clinical or biochemical hyperandrogenism. Combined oral contraceptive (COC) therapy has long been a cornerstone of care for women with PCOS. COC therapy often provides clinical improvement in the areas of excessive hair growth, unpredictable menses, acne, and weight gain. One of the main issues in COC therapy is choosing the most appropriate progestin component to provide the greatest anti androgenic effects. Drospirenone, a relatively new progestin, has shown benefit in the PCOS population when used in conjunction with ethinyl estradiol. We now review the role of COCs in PCOS, focusing specifically on drospirenone. Controversy over metabolic effects of COCs in PCOS is also discussed.

Keywords: polycystic ovary syndrome, PCOS, oral contraceptives, drospirenone, treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Escitalopram tolerability as mono- versus augmentative therapy in patients with affective disorders: a naturalistic study

Dell'Osso B, Arici C, Dobrea C, Camuri G, Benatti B, Altamura AC

Neuropsychiatric Disease and Treatment 2013, 9:205-209

Published Date: 8 February 2013

Chronic shoulder pain referred from thymic carcinoma: a case report and review of literature

Dee SW, Kao MJ, Hong CZ, Chou LW, Lew HL

Neuropsychiatric Disease and Treatment 2012, 8:399-403

Published Date: 4 September 2012

Grid photocoagulation combined with intravitreal bevacizumab for recurrent macular edema associated with retinal vein occlusion

Ogino K, Tsujikawa A, Murakami T, Muraoka Y, Kurashige Y, Yoshimura N

Clinical Ophthalmology 2011, 5:1031-1036

Published Date: 26 July 2011

A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers

Seyed Ali Sadjadi, James I McMillan, Navin Jaipaul, Patricia Blakely, et al.

Therapeutics and Clinical Risk Management 2009, 5:547-552

Published Date: 10 July 2009

Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer

Thérèse H Franco, Ahmed Khan, Vishal Joshi, Beje Thomas

Therapeutics and Clinical Risk Management 2008, 4:1367-1370

Published Date: 5 December 2008

Magnetic nanoparticles for gene and drug delivery

Stuart C McBain, Humphrey HP Yiu, Jon Dobson

International Journal of Nanomedicine 2008, 3:169-180

Published Date: 6 June 2008